Immucell Corp
ICCC- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000811641
No open-market purchases or sales by Immucell Corp insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.4M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +4 vs. previous quarter
- 31
- 13F valueReported value at the end of Q2 2026
- $13.4M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ICCC, Q2 2026
No superinvestor reported holding ICCC at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Immucell Corp insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 22, 2026 (view filing) | Jun 18 | 4 days | te Boekhorst Paul Francis OlivierPresident and CEO | PPurchaseCommon Stock, par value $.01 per share | +8.00K | $9.50 | +$76.0K | +81.8%17.8K after | |
| Dec 4, 2025 (view filing) | Dec 3-4 | 1 day | te Boekhorst Paul Francis OlivierPresident and CEO | PPurchaseCommon Stock $0.10 par value per share | +6.03K | $5.23 | +$31.5K | +162.6%9.74K after | Amended2 lots |
| Nov 28, 2025 (view filing) | Nov 25 | 3 days | Tomsche David ScottDirector | PPurchaseCommon Stock $0.10 par value per share | +1.63K | $4.76 | +$7.77K | +3.2%52.7K after | |
| Nov 28, 2025 (view filing) | Nov 25 | 3 days | Tomsche David ScottDirector | PPurchaseCommon Stock $0.10 par value per share | +1.63K | $4.77 | +$7.79K | +52.6%4.74K after | |
| Jun 12, 2025 (view filing) | Jun 12 | Same day | Gathagan Bryan K.Director | PPurchaseCommon stock $0.10 per value per share | +1.00K | $6.32 | +$6.32K | New position1.00K after | |
| Jun 14, 2022 (view filing) | Jun 13 | 1 day | Cunningham DavidDirector | PPurchaseCommon stock $0.10 per value per share | +1.00K | $8.00 | +$8.00K | +6.7%16.0K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Immucell Corp at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 268,130 | $2.69M | 0.00% | +7,803+3.0% | Added |
| Morgan Stanley | 233,910 | $2.35M | 0.00% | +12,194+5.5% | Added |
| Renaissance Technologies LLC | 171,089 | $1.72M | 0.00% | +19,300+12.7% | Added |
| Cresset Asset Management, LLC | 135,267 | $1.36M | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 72,270 | $726.5K | 0.00% | +6,505+9.9% | Added |
| Dimensional Fund Advisors LP | 58,452 | $587.4K | 0.00% | +2,422+4.3% | Added |
| Bleichroeder LP | 50,000 | $502.5K | 0.09% | −51,594−50.8% | Reduced |
| Steadtrust LLC | 45,370 | $456.0K | 0.23% | −9,000−16.6% | Reduced |
| Mesirow Financial Investment Management, Inc. | 42,481 | $426.9K | 0.01% | 00.0% | Unchanged |
| Citadel Advisors LLC | 40,503 | $407.1K | 0.00% | +4,807+13.5% | Added |